The histone deacetylase inhibitor LBH589 inhibit undifferentiated pleomorphic sarcoma growth via downregulation of FOSL1

被引：0
|
作者：
Saitoh, Yoshinobu [1 ]
Setoguchi, Takao [1 ]
Nagano, Satoshi [1 ]
Taniguchi, Noboru [1 ]
机构：
[1] Kagoshima Univ, Dept Orthop Surg, Kagoshima, Japan
来源：
CANCER SCIENCE | 2018年 / 109卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-3419
引用
收藏
页码：1416 / 1416
页数：1
相关论文
共 50 条
  • [21] The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity
    Woods, David M.
    Woan, Karrune
    Cheng, Fengdong
    Wang, Hongwei
    Perez-Villarroel, Patricio
    Lee, Calvin
    Lienlaf, Maritza
    Atadja, Peter
    Seto, Edward
    Weber, Jeffrey
    Sotomayor, Eduardo M.
    Villagra, Alejandro
    MELANOMA RESEARCH, 2013, 23 (05) : 341 - 348
  • [22] A phase I trial of the histone deacetylase inhibitor panobinostat (LBH589) and epirubicin in patients with solid tumor malignancies.
    Moore, A. P.
    Thomas, S.
    Ryan, C. J.
    Jahan, T. M.
    DuBois, S. G.
    Chan, J. K.
    Thurn, K. T.
    Collisson, E. A.
    Reinert, A.
    Daud, A.
    Munster, P. N.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [23] Molecular Mechanism of the Cell Death Induced by the Histone Deacetylase Pan Inhibitor LBH589 (Panobinostat) in Wilms Tumor Cells
    Tao Yan-Fang
    Li Zhi-Heng
    Xu Li-Xiao
    Fang Fang
    Lu Jun
    Li Gang
    Cao Lan
    Wang Na-Na
    Du Xiao-Juan
    Sun Li-Chao
    Zhao Wen-Li
    Xiao Pei-Fang
    Zhao He
    Su Guang-Hao
    Li Yan-Hong
    Li Yi-Ping
    Xu Yun-Yun
    Zhou Hui-Ting
    Wu Yi
    Jin Mei-Fang
    Liu Lin
    Ni Jian
    Hu Shao-Yan
    Zhu Xue-Ming
    Feng Xing
    Wang Jian
    Pan Jian
    PLOS ONE, 2015, 10 (07):
  • [24] Histone deacetylase inhibitor LBH589 radiosensitizes non-small cell lung cancer by inhibiting DNA repair
    Cuneo, K. C.
    Fu, A.
    Hallahan, D. E.
    Geng, L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 66 (03): : S158 - S158
  • [25] Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome
    Dimicoli, Sophie
    Jabbour, Elias
    Borthakur, Gautam
    Kadia, Tapan
    Estrov, Zeev
    Yang, Hui
    Kelly, Mary
    Pierce, Sherry
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    AMERICAN JOURNAL OF HEMATOLOGY, 2012, 87 (01) : 127 - 129
  • [26] A phase I trial of the histone deacetylase inhibitor panobinostat (LBH589) and epirubicin in patients with solid tumor malignancies.
    Moore, Amy Patricia
    Thach-Giao Truong
    Thurn, Kenneth Ted
    Thomas, Scott
    Ryan, Charles J.
    Jahan, Thierry Marie
    DuBois, Steven G.
    Chan, John K.
    Rugo, Hope S.
    Collisson, Eric Andrew
    Raha, Paromita
    Chen, Stephanie
    Reinert, Anne
    Daud, Adil
    Munster, Pamela N.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [27] Influence of food on the pharmacokinetics (PK) of panobinostat (LBH589), an orally active histone deacetylase inhibitor, in patients with advanced cancer
    Lewis, L.
    Frank, R.
    Dandamudi, U. B.
    Gallagher, J.
    Zhao, L.
    Woo, M.
    Hirawat, S.
    Shapiro, G. I.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [28] Phase II Study of the Histone Deacetylase Inhibitor Panabinostat (LBH589) in Patients with Low or Intermediate-1 Risk Myelodysplastic syndrome
    Dimicoli, Sophie
    Jabbour, Elias
    Borthakur, Gautam
    Kadia, Tapan
    Estrov, Zeev
    Yang, Hui
    Kelly, Mary A.
    Pierce, Sherry
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    BLOOD, 2011, 118 (21) : 755 - 755
  • [29] Histone deacetylase inhibitor (HDACi) LBH589 interference with androgen receptor expression transcriptional activity in prostate cancer cells.
    Thelen, Paul
    Ringert, Rolf-Hermann
    Strauss, Arne
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [30] A Histone Deacetylase Inhibitor LBH589 Downregulates XIAP in Mesothelioma Cell Lines Which is Likely Responsible for Increased Apoptosis With TRAIL
    Symanowski, James
    Vogelzang, Nicholas
    Zawel, Leigh
    Atadja, Petet
    Pass, Harvey
    Sharma, Sunil
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (02) : 149 - 160
12345